Summit Trail Advisors’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.98M | Buy |
16,519
+371
| +2% | +$127K | 0.08% | 153 |
|
|
2026
Q1 | $5.68M | Buy |
16,148
+2,650
| +20% | +$945K | 0.08% | 144 |
|
|
2025
Q4 | $4.42M | Sell |
13,498
-1,840
| -12% | -$584K | 0.08% | 148 |
|
|
2025
Q3 | $4.33M | Buy |
15,338
+323
| +2% | +$93.7K | 0.06% | 167 |
|
|
2025
Q2 | $4.19M | Buy |
+15,015
| New | +$4.25M | 0.07% | 143 |
|
|
2024
Q4 | – | Sell |
-7,552
| Closed | -$2.43M | – | 416 |
|
|
2024
Q3 | $2.43M | Buy |
7,552
+2,163
| +40% | +$708K | 0.06% | 140 |
|
|
2024
Q2 | $1.68M | Buy |
5,389
+231
| +4% | +$67.9K | 0.04% | 162 |
|
|
2024
Q1 | $1.47M | Buy |
5,158
+425
| +9% | +$124K | 0.04% | 166 |
|
|
2023
Q4 | $1.36M | Sell |
4,733
-233
| -5% | -$63.5K | 0.05% | 131 |
|
|
2023
Q3 | $1.33M | Buy |
4,966
+670
| +16% | +$167K | 0.05% | 128 |
|
|
2023
Q2 | $954K | Buy |
4,296
+1,941
| +82% | +$450K | 0.04% | 177 |
|
|
2023
Q1 | $569K | Sell |
2,355
-283
| -11% | -$69.5K | 0.02% | 203 |
|
|
2022
Q4 | $693K | Buy |
2,638
+255
| +11% | +$68.4K | 0.03% | 142 |
|
|
2022
Q3 | $537K | Buy |
2,383
+574
| +32% | +$139K | 0.03% | 167 |
|
|
2022
Q2 | $440K | Buy |
1,809
+587
| +48% | +$144K | 0.03% | 206 |
|
|
2022
Q1 | $295K | Sell |
1,222
-21
| -2% | -$4.82K | 0.02% | 248 |
|
|
2021
Q4 | $280K | Sell |
1,243
-477
| -28% | -$101K | 0.02% | 237 |
|
|
2021
Q3 | $366K | Buy |
1,720
+326
| +23% | +$75K | 0.03% | 185 |
|
|
2021
Q2 | $340K | Buy |
1,394
+96
| +7% | +$23.6K | 0.03% | 165 |
|
|
2021
Q1 | $323K | Buy |
1,298
+159
| +14% | +$37.9K | 0.03% | 150 |
|
|
2020
Q4 | $262K | Sell |
1,139
-572
| -33% | -$132K | 0.03% | 158 |
|
|
2020
Q3 | $406K | Buy |
1,711
+557
| +48% | +$138K | 0.08% | 124 |
|
|
2020
Q2 | $272K | Buy |
+1,154
| New | +$263K | 0.05% | 126 |
|
|
2018
Q4 | – | Sell |
-1,390
| Closed | -$288K | – | 119 |
|
|
2018
Q3 | $288K | Buy |
+1,390
| New | +$274K | 0.06% | 156 |
|
|
2018
Q2 | – | Sell |
-2,843
| Closed | -$434K | – | 490 |
|
|
2018
Q1 | $434K | Buy |
2,843
+225
| +9% | +$41.3K | 0.07% | 226 |
|
|
2017
Q4 | $492K | Buy |
+2,618
| New | +$463K | 0.06% | 231 |
|
Other funds holding AMGN
Summit Trail Advisors's AMGN Position: Q2 2026 in Review
Summit Trail Advisors increased its Amgen (AMGN) stake by 2.3% in Q2 2026, buying an estimated $127K and bringing the position to 16,519 shares worth $5.98M. The position accounts for 0.08% of the portfolio, ranked #153.
Summit Trail Advisors first reported a position in AMGN in Q4 2017 and has held it in 26 quarters since. 3,170 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.
- Summit Trail Advisors held 16,519 shares of Amgen worth $5.98M as of Q2 2026.
- Summit Trail Advisors bought 371 Amgen shares in Q2 2026, an estimated $127K.
- Amgen made up 0.08% of Summit Trail Advisors's portfolio in Q2 2026, its #153 holding.
- Summit Trail Advisors first reported a position in Amgen in Q4 2017 and has held it in 26 quarters since.
- 3,170 funds tracked by Wall St. Rank held Amgen as of Q2 2026.
Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.